01 November 2018
According to lead researcher Geng Meiyu, GV-971, a multi-targeting oligosaccharide drug developed by a Chinese research group, could give Alzheimer patients hope.
GV-971 was developed by Ocean University of China, Shanghai Institute of Materia Medicaunder Chinese Academy of Sciences and Green Valley Pharmaceutical Co., Ltd, after a 21-year study.
The drug completed phase 3 clinical trial in July this year. A phase three clinical trial is the last test before reaching the market. In the trial, participants took 450 mg GV-971 orally twice a day for 36 weeks, which proved effective in improving cognition.
Extracted from brown algae, the drug is targeted at patients with mild-to-moderate Alzheimer’s. Independent animal experiments also showed that it can regulate the immune system, reduce neuro-inflammation and improve cognition.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024